Gary Novack, PhD
Gary D. Novack, PhD is a board certified clinical pharmacologist specializing in ophthalmology. In his 25+ years at PharmaLogic Development, Inc., he has provided critical roles in development and approval of 50 products, including the first pharmacological treatment for macular degeneration, the first site-active corticosteroid, the first and second intravitreal drug delivery systems and the first neurological indications for botulinum toxins. He has published over 260 papers and serves on several editorial boards. He is also a Visiting Professor at the University of California, Davis School of Medicine in the Departments of Pharmacology and Ophthalmology and is a Regent Emeritus of the University of California. Most recently, he chaired the Clinical Trials and Regulatory sub-committee of the Dry Eye Workshop II.